Full Press Release Details
eXoZymes achieves 100 scale-up of NCT production
using exozymes, demonstrating near-perfect feedstock conversion.
Los Angeles, CA - December 11, 2025 - Today, eXoZymes Inc.
(NASDAQ: EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals
and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process
using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock
to product, marks a major milestone in the scalability of the exozymes platform.
"Scaling a complex biocatalytic reaction by 100 while sustaining
high feedstock conversion strengthens our belief that exozymes will form the foundation of the next generation of biomanufacturing,"
said Michael Heltzen, CEO of eXoZymes. "We're very enthusiastic about this progress and see it as an important inflection
point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the door
to producing molecules that have historically been constrained by traditional manufacturing approaches."
The scaled reaction maintained exceptionally high conversion efficiency,
demonstrating near-complete transformation of input feedstock into target product under large-volume operating conditions. This performance
confirms that the exozyme-driven process not only scales linearly but can match - or exceed - conversion levels observed at smaller scales.
The batch production was executed using standardized protocols under partner-operated conditions by Cayman Chemical, underscoring
the robustness, transferability, and scalability of the process and technology.
Dr. Tyler Korman, CSO of eXoZymes, adds, "Scaling while preserving
reaction performance has historically been challenging, and this outcome supports the growing body of evidence that cell-free enzyme production
pathways - aka exozymes systems - can overcome fundamental limitations associated with traditional biomanufacturing approaches. Achieving
over 99% conversion at scale is a significant validation of our exozyme biosolution - both from a scientific as well as a commercial point
Cayman Chemical and eXoZymes are working on the isolation process for NCT
as well as still analyzing the data from the experiment. Additional technical details are expected to be published in a subsequent press
release following completion of downstream analysis and NCT extraction. Due to the magnitude of the work and the upcoming holidays, this
additional information should not be expected until early 2026.
Cayman Chemical helps make research possible by providing
products and services to scientists worldwide. Cayman's collection includes high-quality biochemicals, assay kits, antibodies,
and proteins, empowering researchers to understand the biological mechanisms of health and disease and develop new therapies. Cayman's
scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles
to complex biolipids, and fatty acids, and are highly skilled in all aspects of assay and antibody development, protein expression,
crystallization, and structure determination. In addition, Cayman offers a wide range of analytical services using LC-MS/MS, HPLC, GC,
and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech
Learn more at www.caymanchem.com
Founded in 2019, the company
has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and
optimize nature's own natural processes to produce very valuable natural products, via a commercially scalable, sustainable, and
eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to
thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction
with sustainable and scalable biosolutions that transform biomass into essential chemicals, nutraceuticals and medicines.
By freeing enzyme-driven chemical reactions from the limitations imposed
by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio)
space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes"
as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next
generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more at exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and
describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms
such as "believe," "expect," "may," "will," "should," "would,"
"could," "seek," "intend," "plan," "goal," "project," "estimate,"
"anticipate," "strategy," "future," "likely," "potential," or other comparable
terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical
facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs,
plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully
consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form
10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange
Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does
not give any assurance that it will achieve its expectations.
Lasse G rlitz, VP of Communications